Molecular mechanisms underlying progression from chronic phase to blast crisis are not well understood. Blast crisis is characterised by the acquisition of chromosomal and molecular abnormalities favoured by genomic instability that lead to enhanced survival and differentiation arrest of the malignant clone. Several mechanisms have been described to contribute to these features, and, in particular, downregulation of C/EBPa and upregulation of HOXA9 and EVI1. 4 We report here the case of a 56-year-old man for whom CML in chronic phase was diagnosed on 5 September 2002. In his medical history, we noted a prostate adenoma, arterial hypertension and hypercholesterolemia. He was initially asymptomatic. Leukocytes were at 213 G/L (blasts 2%, basophils 0%) and platelets at 111 G/L. Sokal prognostic score was intermediate. Cytogenetic analysis did not show additional abnormalities, and molecular analysis revealed the M-BCR form of BCR-ABL (p210). He was first treated with hydroxyurea. A well-tolerated combination of interferon and cytarabin started on 25 November 2002 has led to complete haematological remission. However, a haematological relapse (leukocytes 38.800 g/l, blasts 2%, basophils 1%) occurred on 14 February 2003. We then started IM at 400 mg/day. This treatment was also well tolerated and a second haematological remission was obtained within a month. However, BCR-ABL transcript levels after 3 months of this treatment remained stable. At 4 months after the onset of IM, the complete haematological response continued, but cytogenetic analysis concluded in the persis- 7.5 Â 10 6 /kg of recipient weight. He recovered from neutropenia 12 days after reinjection and we observed a rapid elevation of the leukocytes (mature granulocytes without blast excess) with a full recipient chimaerism phenotype. IM therapy at 400 mg/day during 10 days followed by busulphan treatment at 2 mg/day during 1 month, combined with the withdrawal of the immunosuppressive therapy, allowed haematological remission. Chimaerism was then converted to full-donor phenotype. The evolution was marked with undetectable levels of BCR-ABL transcripts (Figure 1) , and by the onset of a grade IV cutaneous GVH controlled by reintroduction of an immunosuppressive therapy.
At the time of emergence of the trisomy 21, screening for a mutation in the AML1/RUNX1 gene by direct sequencing revealed a missense mutation R139P within the runt domain. This mutation is known to confer loss of function of this gene (impaired DNA binding and transactivation). The same findings were noted on accelerated phase samples and the retrospective analysis of samples from diagnosis demonstrated the presence of this mutation in a heterozygous form. Furthermore, we identified by direct sequencing a BCR-ABL M244V mutation at the time of IM resistance and acceleration. This mutation was not present in previous samples, and in particular was not found at the diagnosis of the disease.
AML1 is a major gene contributing to definitive haematopoiesis. Clustered mutations in the AML1 runt terminal region were mainly described in (i) AML-M0 (often biallelic mutations), (ii) familial platelet disorder (inherited AML1 heterozygous mutation leading to AML predisposition), (iii) haematological malignancies with trisomy 21, and (iiii) MDS/AML secondary to ionising radiation or chemotherapeutic agents exposition. [5] [6] [7] More recently, mutations in the C-terminal region of the gene have been described, especially in MDS/AML. 8 To our knowledge, it is the first time that an AML1/RUNX1 mutation is described in CML in chronic phase. Here, we observed the acquisition of a trisomy 21 in the Ph1 þ clone, which is a rare event in the course of CML. The duplication of chromosome 21 bearing the mutated AML1 gene occurred only 2 months before the accelerated phase and may have contributed to the differentiation arrest associated with the progression of CML.
As a result of its low IC 50 assessed by biochemical analysis, 9 the BCR-ABL M244V mutation probably does not induce an effective resistance to IM. Nevertheless, both BCR-ABL and AML1/RUNX1 mutations may reflect genomic instability, and the further acquisition of trisomy 21 and subsequent duplication of the mutated AML1/RUNX1 allele could represent a major event responsible for the progression of CML. This observation underlies the possible molecular heterogeneity of CML at diagnosis. Factors that could define more precisely the disease at diagnosis (such as microarray analysis or the screen for mutation in some defined genes, such as AML1/ RUNX1 when trisomy 21 is observed) may be complementary to the classical scores (such as Sokal and Hasford scores) for therapeutic decision adjustment.
